Evidence map›Paper›PMID 32313074›Full record

ReviewCommunications biology2020

The bidirectional relationship between CFTR and lipids.

Kirsten A Cottrill, Carlos M Farinha, Nael A McCarty

Abstract readReview
In one paragraph

Review in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Protein interactions, calcium, phosphorylation, and cholesterol modulate CFTR cluster formation on membranes.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Databases of ligand-binding pockets and protein-ligand interactions.Computational and structural biotechnology journal · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Cell type-specific regulation of CFTR trafficking-on the verge of progress.Frontiers in cell and developmental biology · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kirsten A CottrillMolecular and Systems Pharmacology PhD Program, Emory University, Atlanta, GA, USA.
Carlos M FarinhaBiosystems and Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, 1749-016, Lisboa, Portugal.
Nael A McCartyMolecular and Systems Pharmacology PhD Program, Emory University, Atlanta, GA, USA. namccar@emory.edu.

Funding

Graduate Training in the Pharmacological StudiesT32GM008602 · NIGMS · EMORY UNIVERSITY · PI HALL, RANDY A. · 1996 to 2021
$5.1M
Determining the Physiological Mechanism of CFTR Inhibition by SphingomyelinaseF31HL143863 · NHLBI · EMORY UNIVERSITY · PI COTTRILL, KIRSTEN ALYSSA · 2018 to 2020
$133k
NHLBI NIH HHS F31 HL143863NIGMS NIH HHS T32 GM008602
6 · The paper itself

Abstract

Cystic Fibrosis (CF) is the most common life-shortening genetic disease among Caucasians, resulting from mutations in the gene encoding the Cystic Fibrosis Transmembrane conductance Regulator (CFTR). While work to understand this protein has resulted in new treatment strategies, it is important to emphasize that CFTR exists within a complex lipid bilayer - a concept largely overlooked when performing structural and functional studies. In this review we discuss cellular lipid imbalances in CF, mechanisms by which lipids affect membrane protein activity, and the specific impact of detergents and lipids on CFTR function.

Indexed as

AminophenolsAminopyridinesAnimalsBenzodioxolesCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsEpithelial CellsHumansLungMembrane LipidsMembrane MicrodomainsMutationProtein ConformationProtein StabilityProtein TransportAminophenolsAminopyridinesBenzodioxolesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationsivacaftorlumacaftorlumacaftor, ivacaftor drug combinationMembrane LipidsQuinolones

Identifiers

PMID32313074
PMCPMC7170930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.